An upcoming study will test a smartphone application as a novel tool for assessing symptoms, disease progression, and severity in patients with myasthenia gravis (MG).
Researchers will soon initiate this observational, retrospective study that plans to include 120 adult participants previously diagnosed with MG.
The application consists of a digital platform that patients can download onto their smartphones to independently monitor their symptoms between hospital visits. It will include at least 5 different tests that evaluate respiratory capacity, dysarthria, ptosis, and upper and lower limb function, named “My Breathing,” “My Voice,” “My Eyelids,” “My Arms,” and “My Legs,” respectively.
Read more about MG diagnosis
Another function consists of questionnaires through which the users can report daily living activities, quality of life, sleep parameters, pain, and depression.
The main goals of this study are to determine real-life data regarding the muscular function of individuals with MG. For example, the software will evaluate respiratory capacity by time in seconds through the patient saying “aaahh,” margin-reflex distance 1 will measure ptosis while holding the phone in one arm as long as possible, and the number of sit-to-stand movements achieved in 1 minute will report upper and lower limb impairment.
Measuring the overall reliability, adherence, satisfaction, user behavior, and safety of these digital tests and questionnaires constitute the secondary outcomes. Moreover, the researchers will analyze potential associations between the application usage and the sociodemographic features of the sample. The application may also help identify patterns regarding symptom worsening and early signs of depression.
Patients with positive auto anti-acetylcholine receptor antibodies that own and are able to use a smartphone can become part of the sample.
This research, designed to evaluate the application “ME&MGopen” as a potential tool for identifying and predicting patterns in patients with MG, will possibly start in December 2022 and is expected to be completed by December 2024.
Descriptive analysis of real-world data collected with ME&MGopen. ClinicalTrials.gov. October 5, 2022. Updated October 20, 2022. Accessed October 20, 2022.